Highlights
- Market Cap
- $5.64B
- Enterprise Value
- $17.04B
- EPS (TTM)
- $6.82
- PE Ratio
- 1.11
- Total Revenue (TTM)
- $217.48B
- Gross Profit (TTM)
- $23.43B
- EBITDA (TTM)
- $7.58B
- Year Range
- $6.39 - $8.32
- ROA (TTM)
- 15.19%
- ROE (TTM)
- 47.47%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Shanghai Pharmaceuticals Holding Co Ltd ADR, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Shanghai Pharmaceuticals Holding Co Ltd ADR (SHPMY) has returned -7.65% so far this year and 7.82% over the past 12 months.
Shanghai Pharmaceuticals Holding Co Ltd ADR
- 1D
- 0.00%
- 1M
- 7.50%
- YTD
- -7.65%
- 6M
- -7.48%
- 1Y
- 7.82%
- 3Y*
- -2.66%
- 5Y*
- -0.39%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Oct 9, 2017, SHPMY's average daily return is +0.04%, while the average monthly return is +0.08%. At this rate, your investment would double in approximately 72.2 years.
Historically, 42% of months were positive and 58% were negative. The best month was Nov 2022 with a return of +21.3%, while the worst month was Apr 2022 at -20.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.
On a daily basis, SHPMY closed higher 30% of trading days. The best single day was Mar 21, 2022 with a return of +26.4%, while the worst single day was Mar 24, 2020 at -13.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.00% | -14.09% | 7.50% | -7.65% | |||||||||
| 2025 | -7.02% | -6.19% | 0.69% | -6.69% | 0.00% | 0.00% | 20.39% | 0.00% | 3.75% | -0.84% | 0.00% | 1.04% | 2.54% |
| 2024 | 1.60% | 13.03% | -11.59% | 3.09% | 2.80% | -4.02% | 9.19% | -12.44% | 20.43% | 0.44% | 5.09% | -3.17% | 21.54% |
| 2023 | 8.95% | 1.31% | 4.50% | 7.12% | -2.29% | -0.31% | -0.23% | -10.33% | -7.02% | -4.31% | -0.87% | -2.65% | -7.55% |
| 2022 | 3.13% | -7.76% | 12.46% | -20.18% | 5.22% | -4.96% | -1.05% | -3.28% | -4.78% | -0.95% | 21.33% | -0.89% | -7.32% |
| 2021 | 0.48% | 5.48% | 15.59% | 11.05% | -0.53% | -3.54% | -0.01% | -6.76% | 3.06% | -9.95% | 1.26% | 3.13% | 17.96% |
Benchmark Metrics
Shanghai Pharmaceuticals Holding Co Ltd ADR has an annualized alpha of 6.60%, beta of 0.21, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since October 11, 2017.
- This stock participated in 93.45% of S&P 500 Index downside but only 39.53% of its upside — more exposed to losses than it benefited from rallies.
- Beta of 0.21 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 6.60%
- Beta
- 0.21
- R²
- 0.01
- Upside Capture
- 39.53%
- Downside Capture
- 93.45%
Return for Risk
Risk / Return Rank
SHPMY ranks 56 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Shanghai Pharmaceuticals Holding Co Ltd ADR (SHPMY) and compare them to a chosen benchmark (S&P 500 Index).
| SHPMY | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.28 | 0.90 | -0.62 |
Sortino ratioReturn per unit of downside risk | 0.60 | 1.39 | -0.79 |
Omega ratioGain probability vs. loss probability | 1.29 | 1.21 | +0.08 |
Calmar ratioReturn relative to maximum drawdown | 0.56 | 1.40 | -0.84 |
Martin ratioReturn relative to average drawdown | 1.10 | 6.61 | -5.50 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore SHPMY risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Shanghai Pharmaceuticals Holding Co Ltd ADR provided a 3.78% dividend yield over the last twelve months, with an annual payout of $0.29 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend | $0.29 | $0.29 | $0.34 | $0.42 | $0.63 | $0.37 | $0.25 | $0.24 |
Dividend yield | 3.78% | 3.49% | 4.06% | 5.87% | 7.70% | 3.89% | 2.94% | 2.41% |
Monthly Dividends
The table displays the monthly dividend distributions for Shanghai Pharmaceuticals Holding Co Ltd ADR. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.20 | $0.00 | $0.00 | $0.00 | $0.00 | $0.08 | $0.29 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.28 | $0.00 | $0.06 | $0.00 | $0.00 | $0.00 | $0.34 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.42 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.42 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.63 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.63 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.37 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.37 |
Dividend Yield & Payout
Dividend Yield
Shanghai Pharmaceuticals Holding Co Ltd ADR has a dividend yield of 3.78%, which is quite average when compared to the overall market.
Payout Ratio
Shanghai Pharmaceuticals Holding Co Ltd ADR has a payout ratio of 26.56%, which is quite average when compared to the overall market. This suggests that Shanghai Pharmaceuticals Holding Co Ltd ADR strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Shanghai Pharmaceuticals Holding Co Ltd ADR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Shanghai Pharmaceuticals Holding Co Ltd ADR was 53.72%, occurring on Mar 18, 2020. The portfolio has not yet recovered.
The current Shanghai Pharmaceuticals Holding Co Ltd ADR drawdown is 32.45%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -53.72% | May 3, 2018 | 264 | Mar 18, 2020 | — | — | — |
| -11.67% | Feb 8, 2018 | 1 | Feb 8, 2018 | 6 | Apr 9, 2018 | 7 |
| -4.44% | Nov 15, 2017 | 1 | Nov 15, 2017 | 3 | Jan 3, 2018 | 4 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Shanghai Pharmaceuticals Holding Co Ltd ADR over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Shanghai Pharmaceuticals Holding Co Ltd ADR is priced in the market compared to other companies in the Medical Distribution industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for SHPMY, comparing it with other companies in the Medical Distribution industry. Currently, SHPMY has a P/E ratio of 1.1. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SHPMY relative to other companies in the Medical Distribution industry. Currently, SHPMY has a P/S ratio of 0.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SHPMY in comparison with other companies in the Medical Distribution industry. Currently, SHPMY has a P/B value of 0.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |